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Abstract. Loss of T-cadherin expression has been reported
in a number of human cancers. We previously reported
that T-cadherin re-expression suppressed cell growth and
motility in glioma. Here, we report that the T-cadherin
expression was significantly decreased in human hepatocellular carcinoma (HCC) compared to adjacent normal liver.
In addition, T-cadherin expression in HCC with metastasis
was significantly lower than in HCC without metastasis. To
determine the mechanism underlying the reduced T-cadherin
expression in HCC, we examined T-cadherin promoter methylation. We found that methylation of the T-cadherin promoter
was present in 40% of HCC, but absent in all adjacent liver
tissues. In the HCC with T-cadherin promoter methylation,
the T-cadherin expression was significantly decreased
compared to HCC without methylation. To provide a
functional link between T-cadherin promoter methylation and
T-cadherin growth regulation, we used the HepG2 hepatoma
cell line that exhibits T-cadherin promoter methylation.
Treatment of HepG2 cells with the demethylating agent 5-aza2-deoxycytidine resulted in increased T-cadherin expression
and reduced cell proliferation. These results demonstrate that
the T-cadherin down-regulation by promoter methylation is
associated with the development and progression of HCC,
and suggest that T-cadherin is an important tumor suppressor
in liver cancer.
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Introduction
Hepatocellular carcinoma HCC following hepatitis B and C is
a common malignant disease in Asia and Africa. HCC has
become the second most prevalent cause of cancer-related
deaths in mainland China, with about 137,500 deaths per year
(1). Although hepatic resection remains the most effective
treatment (2,3), the high rate of postoperative recurrence and
tumor metastasis inevitably leads to poor clinical outcome.
To develop potential effective treatments for HCC, recent
studies have focused on understanding the molecular pathogenesis of HCC formation and progression. HCC is closely
linked to persistent HBV infection and the intake of α-flatoxin
B-contaminated food (4,5). HCC is hypothesized to represent
a multi-stage process resulting from the accumulation of
genetic changes (6), including p53 (7,8) and Rb inactivation
(9) as well as TGF-ß (10) and Ras (11) activation.
HCC is frequently characterized by portal vein invasion
and metastasis (1). One of the critical steps in carcinoma
invasion and metastasis is the detachment of intercellular
junctions of tumor cells, suggesting that cell surface molecules
important for cell attachment might regulate this process
in HCC. In this regard, the cadherins are transmembrane
glycoproteins which mediate calcium-dependent cell-tocell adhesion, and play important roles in cell adhesion and
cell signal transduction in a number of cell types (12,13).
Studies have shown that the classic cadherin molecules,
E-cadherin and N-cadherin, are involved in the molecular
pathogenesis of breast, lung, gastric and liver cancers (14-18).
Loss of E-cadherin expression has been frequently reported in
a diverse number of malignant tumors and the reintroduction
of E-cadherin into highly invasive tumor cell lines results in
suppression of both invasion and growth (19). In HCC, loss
of E-cadherin expression correlates with hypermethylation
and has been suggested to play an important role in HCC
progression (20). Moreover, E-cadherin promoter methylation in HCC is correlated with microvascular invasion
and recurrence (21,22).
Unlike other cadherins, T-cadherin (for truncatedcadherin) is anchored to the membrane by a glycosylphos-
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phatidylinositol anchor and lacks the conventional transmembrane and cytoplasmic domains (23-25). Previous studies
have shown that T-cadherin mediates calcium-dependent cell
adhesion and colocalizes with small trimeric G-proteins and
SRC family kinases in lipid rafts, where it may be involved
in modulating signal transduction pathways (26-28). Our
previous study demonstrated that T-cadherin overexpression
suppressed cell growth and motility by inducing a p21dependent G2 arrest in glioma cells (29). T-cadherin gene
maps to human chromosome 16q24, and loss of T-cadherin
expression has been reported in sporadic breast and lung
cancers (30-32) pancreatic cancer tumors and cell lines (33),
ovarian cancer (34), cutaneous squamous (35) and HCC (36).
In the current study, we sought to determine the functional
role of T-cadherin in HCC to define the relationship between
T-cadherin expression, promoter methylation and tumor
behavior.
Materials and methods
Patients and specimens. Forty human HCC specimens
and their corresponding adjacent normal liver tissues were
collected from the surgical resection samples at Hepatic
Surgical Center, Tongji Hospital, Huazhong University of
Science and Technology from 2004 to 2005. All tumor
specimens were pathologically diagnosed as HCC. Twenty
specimens diagnosed as poorly-differentiated HCC and
another 20 as moderately- or well-differentiated HCC were
chosen for comparison. Eight out of 40 specimens were
associated with intrahepatic portal vein invasion, whereas the
other 32 specimens lacked intrahepatic portal vein invasion.
Among the 40 patients, 32 patients were men and 8 women,
aged from 30-72 years, with an average of 49.4 years. All
specimens were stored at -80˚C until analysis.
Immunohistochemical staining. Anti-T-cadherin (H126)
polyclonal antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The sections from paraffinembedded specimens were prepared at 4-micrometer
thickness. Antigen retrieval was performed in boiling citrate
buffer for 15 min. Peroxide blocking was preformed with
0.3% peroxide in absolute methanol. After the slides were
incubated with anti-T-cadherin antibody at a 1:100 dilution
at 4˚C overnight and washed twice with PBS, they were
then incubated with secondary antibody (Dako, USA) at
room temperature for 30 min. After washing, sections were
incubated with immunoglobulins conjugated with horseradish peroxidase. Finally, the reaction was developed with
3,3'-diaminobenzidine. Tissue sections were counterstained
with hematoxylin or methyl green. T-cadherin-expressing
positive cells were defined only when T-cadherin staining
was observed around the entire cell membranes. The percentage of positive cells were calculated by divided by the
total number of hepatocytes in least 10 randomly chosen
non-overlapping high-power (x400) fields for each case.
T-cadherin expression was graded on a scale from + to +++.
The percentage of the positive cells ≤25% were graded as
‘+’, including those with absent staining. Tumors with >25%
but <50% T-cadherin-immunoreactive cells were scored as
‘++’, while tumors with >50% were graded as ‘+++’.

DNA extraction and MSP. Briefly, extracting genomic DNA
from tumor tissues, their corresponding liver tissues and
the HepG2 cell line was performed by the digestion with
proteinase K using a Genomic DNA Purification Kit (Gentra,
USA). Following digestion, 1 μg of genomic DNA was
treated with the Chemicon CpG WIZ™ DNA Modification
Kit (Chemicon, USA), which converts all unmethylated
cytosines to uracil, leaving methylated cytosines unchanged
(37). The modified DNA was diluted in TE buffer. Two sets
of primers were used to amplify each region of interest: PCR
amplification was performed with bisulfite-treated DNA as
template using specific primer sequences for the methylated
(i.e., unmodified by bisulfite treatment) and unmethylated
(i.e., bisulfite modified to UpG) forms of the gene. Aberrant
promoter methylation of T-cadherin was determined by the
method of MSP as reported previously (38). Primer sequences
of T-cadherin for the unmethylated reaction were: T-cadherin
UMS (sense), 5'-TTGTGGGGTTGTTTTTTGT-3', and Tcadherin UMAS (antisense), 5'-AACTTTTCATTCATA
CACACA-3', which amplify a 242-base pair product. Primer
sequences of T-cadherin for the methylated reaction were:
T-cadherin MS (sense), 5'-TCGCGGGGTTCGTTTTTC
GC-3', and T-cadherin MAS (antisense), 5'-GACGTTTTCA
TTCATACACGCG-3', which amplify a 243-base pair
product (32). Results were confirmed by repeating bisulfite
treatment and MSP assays for all samples.
RT-PCR. Total RNA was extracted from the HCC cell line
HepG2, HCC tissues and their adjacent liver tissues with
TRIzol (Invitrogen, USA) following the manufacturer's
instructions. RT reaction was performed on 2 μg of total
RNA with the SuperScript II First-Strand Synthesis using
an oligo(dT) primer system (Life Technologies, Inc.).
Primer sequences and conditions for RT-PCR product were
previously described (forward primer, 5'-TTCAGCAGAA
AGTGTTCCATAT-3' and reverse primer, 5'-GTGCAT
GGACGAACAGAGT-3') (33,39). The housekeeping gene
GAPDH was used as an internal control of the RT reaction
(forward primer, 5'-AGAAGGCTGGGGCTCATTTG-3'
and reverse primer, 5'-AGGGGCCATCCACAGTCTTC-3').
PCR was carried out for 32 cycles. The PCR amplification
consisted of 1 cycle of 94˚C for 5 min; 30 cycles of 94˚C
for 30 sec, 50˚C for 1 min, and 72˚C for 1 min; and 1 cycle
of 72˚C for 10 min. PCR products were analyzed on 2%
agarose gels.
Western blotting. HepG2 cells and 5-aza-2-deoxycytidinetreated cells were lysed with sodium dodecyl sulfate (SDS)
sample buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl,
0.02% sodium azide, 100 μg/ml phenylmethylsulfonyl fluoride, 50 mM DTT, 1 μg/ml aprotinin and 1% Triton X-100).
Liver tissues were homogenized using a homogenizer in
RIPA lysis buffer (50 mM Tris-HCl, pH 8.0, 1% NP40, 0.1%
SDS, 100 μg/ml phenylmethylsulfonyl fluoride, 0.5% sodium
deoxycholate, 0.02% sodium azide, 1 μg/ml aprotinin and
150 Mm NaCl) on ice. The supernatants were collected after
centrifugation at 14,000 x g at 4˚C for 10 min. After protein
concentration was determined, and whole-tissue lysates
were mixed with an equal amount 5X SDS loading buffer
(125 mM Tris-HCl, 4% SDS, 20% glycerol, 100 mM DTT
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Figure 1. T-cadherin immunohistochemical staining shows reduced
expression in HCC. (A) HCC tissue, arrow indicating cells with loss of
T-cadherin expression. (B) Adjacent liver tissue, arrow showing cells with
normal T-cadherin expression. (C) Semiquantitative analysis of T-cadherin
expression in HCC tissues and their adjacent liver tissues. P-value corresponds to the comparison of T-cadherin expression in the HCC tissues and
their adjacent liver tissues.

1059

cells were seeded on 18 6-cm diameter plates, and the
medium was changed every three days. The plates were
divided into two groups, each with 9 plates. One group was
cultured with DMEM only, while the other group was
cultured with DMEM plus the demethylation agent at 2 μM.
Medium was changed every 2-3 days. Cell numbers were
counted on days 3, 6 and 9 after seeding. The optimum
concentration of demethylation agent was determined by
culturing HepG2 cells with different concentrations of 5-aza2-deoxycytidine at 0, 1, 2, 4, 8, 10, 20 and 40 μmol/ml,
respectively. Two μM was chosen as optimum concentration
because it was the highest concentration at which the cells
survived well and no drug-related cell death was observed
in the culture. After cell counting, the cells of the two groups
were subject to Western blot.
Data analysis. Statistical differences between groups were
examined using Fisher's exact test. P-values of 0.05 were
regarded as statistically significant.
Results

and 0.2% bromophenol blue), as described previously (40).
Samples were heated at 100˚C for ~ 5-10 min before loading
and were separated on pre-casted 10% SDS-polyacrylamide
gels (Fluka, USA). Proteins were electrotransferred onto
nitrocellulose membranes (Invitrogen, USA) in transfer
buffer. Non-specific binding to the membrane was blocked
for 1 h at room temperature with 5% non-fat milk in TBS
buffer (20 mM Tris-HCl, 150 mM NaCl and 0.1% Tween20). Membranes were then incubated for overnight at 4˚C
with anti-T-cadherin antibody at a 1:1,000 dilution. The
membranes were then incubated with horseradish peroxidaseconjugated secondary antibody at 1:5,000 dilution for 1 h at
room temperature in 1% non-fat milk dissolved in TBS.
Membranes were then washed with TBS buffer, and signals
visualized using the enhanced chemiluminescence system
(Pierce, USA).
Cell culture and cell growth. HepG2 liver cancer cells were
cultured in Dulbecco's modified Eagle's medium (DMEM)
supplemented with 10% fetal bovine serum and penicillinstreptomycin. To establish HepG2 cell growth curves, 104

T-cadherin expression is down-regulated in HCC comparing
to its corresponding liver tissue. By immunohistochemical
staining, T-cadherin expression was located along the plasma
cell membrane of hepatocytes in adjacent normal liver tissues
(Fig. 1B), however, varying degrees of loss of T-cadherin
expression were observed in HCC cells (Fig. 1A). There was
a significantly difference in T-cadherin expression between
HCC and the corresponding liver tissue (P<0.01) (Fig. 1C).
Down-regulation of T-cadherin is closely associated with
the malignant biological characteristics of HCC. To evaluate
the correlation between the T-cadherin expression and the
biological characteristics of HCC, T-cadherin expression
was studied in 20 poorly-differentiated HCC and another
20 moderately- and well-differentiated HCC. The T-cadherin
expression loss in the poorly-differentiated HCC were
comparable to those in the moderately- and well-differentiated
HCC (24.7% vs. 35.1%), there was no significant difference
in T-cadherin expression (P=0.194) (Fig. 2A). However, in 8
specimens from the patients associated with intrahepatic
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Figure 2. Semiquantitative analysis of T-cadherin expression in well- and moderately-differentiated HCC as well as poorly-differentiated HCC (A), and in
HCC with and without portal vein metastasis (B). P-values correspond to the comparison of T-cadherin expression between the two groups.

Figure 3. Correlation between T-cadherin promoter methylation and T-cadherin mRNA and protein expression. (A) Cases 2, 6, 9, 17 and HepG2 cells indicate
T-cadherin promoter methylation present in HCC tissues and HepG2 cells and absent in their adjacent liver tissues. ‘T’ represents for HCC tissue, ‘N’ for
adjacent liver tissue; ‘m’ and ‘u’ represent for methylation and unmethylation status, respectively. (B) T-cadherin mRNA expression in cases 2, 6, 9 and 17.
T-cadherin mRNA expression in HCC samples was significantly decreased compared to their corresponding adjacent liver tissues. GAPDH was used as an
internal control. (C) Western blotting shows the pattern of T-cadherin protein expression in HCC tumors from cases 2, 6, 9 and 17. ß-actin was used as an
internal control.

portal vein invasion, the T-cadherin expression was significantly lower than in the other 32 specimens from patients
without intrahepatic portal vein invasion (13.1% vs. 34.1%,
P=0.01) (Fig. 2B).

Aberrant methylation contributes to the down-regulation of
T-cadherin expression. To explore whether aberrant promoter
methylation was responsible for the down-regulation of
T-cadherin expression in HCC tissues, T-cadherin promoter
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Table I. T-cadherin methylation status and clinicopathological findings in 20 HCC patients.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Case Age Sex
no.

Tumor
size (cm)

Portal vein Cirrhosis Differentiation
thrombus

T-cadherin expression rate
HBV or HCV Methylation ––––––––––––––––––––––
infection
status
HCC
Adjacent liver
%
tissue %

–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
1
2
6
9
10
15
17
19
3
4
5
7
8
11
12
13
14
16
18
20

52
30
46
48
48
59
53
45
62
46
53
72
35
46
47
50
52
53
54
36

M
M
F
M
F
M
M
M
M
F
M
M
M
M
M
F
F
M
M
F

3.5x3x2.5
11x6x8
13x12x9.5
4x2.5x2
8x7x4.5
5x3x3.5
10x2x8
5x4.5x2
6x6x3.5
3.2x3x2
7x7x3
2.5x1x1.5
10x9x8
4x3x2
4x4x2
12x10x9
8x7.4x6
10x7.5x8
3x1.5x1.5
14x8x9

+
+
+
+
+
+
+
+
-

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Poor
Mod
Mod
Poor
Well
Poor
Well
Poor
Poor
Mod
Well
Well
Mod
Poor
Mod
Mod
Uncertain
Poor
Well
Mod

B
B
B
B
B
B
B
B
B
B
B
B
B
C
B
B
B
B
B

+
+
+
+
+
+
+
+
-

25
0
15
3
11
24
9
10
30
23
31
6
65
45
47
34
45
13
34
24

54
37
34
43
40
28
45
28
54
78
79
80
67
60
67
65
76
23
60
27

–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––

Figure 4. Semiquantitative analysis of T-cadherin protein expression in
HCC with and without T-cadherin promoter methylation. P-value
corresponds to the comparison of T-cadherin positive expression in the
two groups.

methylation status and the correlation between the promoter
methylation status and T-cadherin expression were investigated in 20 HCC specimens and their non-malignant
counterparts. Promoter methylation was present in the 8 HCC
specimens and absent in all adjacent liver tissues (Fig. 3A).
T-cadherin methylation status and the clinicopathological
characteristics of the 20 HCC patients are shown in Table I.
RT-PCR analysis confirmed that T-cadherin mRNA was

significantly decreased or absent in all 8 HCC compared to
their adjacent liver tissues (Fig. 3B). Furthermore, Western
blot study demonstrated that T-cadherin protein expression
in 8 HCC samples with T-cadherin promoter methylation
was significantly decreased compared to their adjacent liver
tissues (Fig. 3C). Semiquantitative analysis of immunohistochemical staining indicated that the average T-cadherin
expression rate of 8 HCC with the promoter methylation was
significantly lower than that of the other 12 HCC without
promoter methylation (15.5% vs. 30.8%, P=0.04) (Fig. 4),
suggesting that the promoter methylation contributes to the
regulation of T-cadherin expression in HCC. Furthermore,
among the 8 HCC with promoter methylation, 5 HCC tumors
(5/8) were associated with portal vein tumor thrombus,
indicating that the T-cadherin down-regulation by promoter
methylation is associated with the development of portal vein
tumor thrombus in HCC. However, among the 20 HCC, there
were 17 HCC with decreased T-cadherin mRNA and protein
expression compared to their adjacent liver tissues, only 8
HCC were found with T-cadherin promoter methylation.
These data demonstrate that the promoter methylation is
involved in the down-regulation of T-cadherin in HCC, but
that other mechanisms are involved in T-cadherin regulation.
Demethylation results in increased T-cadherin expression
and reduced HepG2 cell growth. We first showed that the
human hepatoma cell line HepG2 exhibit T-cadherin promoter
methylation (Fig. 3A). To study whether demethylation
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Figure 5. The demethylating agent 5-aza-2-deoxycytidine restores T-cadherin
expression in HepG2 cells and suppresses cell growth. (A) Western blotting
indicating a significant increase in T-cadherin expression after cells were
treated with 5-aza-2-deoxycytidine at 2 μg/ml for 9 days, compared to cells
without treatment. ß-actin was used as an internal control. (B) Growth curves
demonstrating reduced cell numbers in the 5-aza-2-deoxycytidine-treated
group at different time points.*Represents a significant statistic difference
(P<0.05).

agents can restore T-cadherin expression in HepG2 cells,
HepG2 cells were treated with 2 μM of the demethylation
agent 5-aza-2-deoxycytidine for 9 days, and the cell number
determined on days 3, 6 and 9 after initial seeding. Western
blot demonstrated that T-cadherin expression in the 5-aza2-deoxycytidine-treated cells was significantly increased
compared to those untreated control cells (Fig. 5A). Moreover,
T-cadherin re-expression was associated with decreased cell
growth following 5-aza-2-deoxycytidine treatment (P<0.05)
(Fig. 5B).
Discussion
Studies of the underlying molecular mechanisms involved
in HCC formation and progression provide tremendous
opportunities to identify key molecules which may serve as
additional targets for drug design in the treatment of liver
tumors. Using molecular analysis, loss of heterozygosity has
been found in several chromosomes in patients with HCC
(20). Many of these chromosomal segments contain known
tumor suppressor genes, such as p53 on 17p, p16 on 9p, and
RB on 13q. Mutations and overexpression of several
oncogenes including ras, TGF-ß and c-myc have been
identified in HCC patients (21-26). In light of previous studies
implicating cadherin family members, such as E-cadherin
and N-cadherin, in the molecular pathogenesis of liver cancers
(17,20), we examined the expression and methylation of a
novel member of the cadherin family, T-cadherin. T-cadherin
is a truncated-cadherin that plays an important role not

only in cell-cell adhesion but also in maintaining the normal
cellular phenotype (23). Recent studies revealed that reexpression of T-cadherin in breast cancer cells (41) and
glioma cell lines (29) inhibited the invasive potential and
cell growth of tumor cells in vitro. T-cadherin maps to
chromosome 16q24, and loss of chromosome 16q is one of
most prevalent genetic alterations in HCC (42); however,
T-cadherin expression in HCC and the relationship between
T-cadherin expression and HCC progression have not
previously been investigated in human HCC.
In our study, we demonstrated that T-cadherin expression
was significantly decreased in HCC compared to their
adjacent liver tissues. We also showed that decreased Tcadherin expression correlated with HCC portal vein invasion,
suggesting that loss of T-cadherin was also involved in the
progression of HCC.
Aberrant methylation of T-cadherin promoter is one of
the major mechanisms for the inactivation or downregulation of T-cadherin expression in a number of tumor
types, including breast cancer (43), lung cancer (44,45) and
colorectal cancer (46). Our studies indicated that in HCC,
aberrant methylation of T-cadherin promoter was present
in 8 of 20 HCC, and these 8 HCC tumors with promoter
methylation had reduced T-cadherin mRNA and protein
expression. Compared to the T-cadherin expression in other
12 HCC tumors without methylation, T-cadherin expression
in 8 HCC tumors with T-cadherin promoter methylation
was significantly deceased (P<0.05), suggesting that
promoter methylation contributes to the decreased Tcadherin expression observed in HCC. Among the 8 HCC
tumors with the promoter methylation, 5 were associated
with portal vein invasion; while in the other 12 HCC tumors
without promoter methylation, only three HCC were with
portal vein invasion.
To determine whether T-cadherin promoter methylation
contributes to the increased growth of HCC tumors, HepG2
cells were used to study whether treat-ment with a
demethylation agent can restore T-cadherin expression. We
found that the demethylation agent 5-aza-2-deoxycytidine
was able to restore T-cadherin expression in HepG2 cells
and reduce HepG2 cell growth.
Collectively, our data demonstrate that loss of T-cadherin
expression resulting from the promoter methylation plays
a role in the molecular pathogenesis of HCC, and suggest
that T-cadherin promoter methylation contributes to the
reduction in T-cadherin expression in these tumors. Future
studies on T-cadherin regulation may result in the development of novel targets for HCC therapies.
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